Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
The FDA has approved Pfizer’s biosimilar drug, Retacrit, a cut price competitor Amgen and Johnson & Johnson's bone marrow stimulating drug epoetin alfa. Retacrit (epoetin alfa-epbx), is a biosimilar ...
Hospira, Inc. HSP presented data from two studies on a proposed biosimilar, Retacrit (Epoetin Hospira), at the National Kidney Foundation spring meeting. The drug is a proposed biosimilar to Amgen Inc ...
The Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx), a biosimilar of Epogen/Procrit (epoetin alfa), to treat anemia caused by a number of factors – including undergoing ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback